New Stocks to Watch in Cleantech, Mining and Retail Sectors; (NASDAQ: $BNRG), (CSE: $BSKY.CN) (OTCQB: $BSKCF), (Nasdaq: $DEVS), (NASDAQ: $LNZA), (NASDAQ: $NITO), (TSX: $FFM.TO) (TSXV: $AGA.V), (TSX: $GRGD.TO)

New Stocks to Watch in Cleantech, Mining and Retail Sectors; (NASDAQ: $BNRG), (CSE: $BSKY.CN) (OTCQB: $BSKCF), (Nasdaq: $DEVS), (NASDAQ: $LNZA), (NASDAQ: $NITO), (TSX: $FFM.TO) (TSXV: $AGA.V), (TSX: $GRGD.TO)

 

 

 

January 31, 2025 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Cleantech, Mining and Retail sectors.

 

The newest cleantech companies are involved in carbon credits, CO2 recycling, sustainable solutions for energy and agritech, and energy storage.

 

The latest mining companies explore for copper-gold/vanadium and silver, respectively.

 

The newest retail company offers women's fashion apparel.

 

New stocks added today: Brenmiller Energy, Ltd. (NASDAQ: BNRG), BluSky Carbon Inc. (CSE: BSKY) (OTCQB: BSKCF), DevvStream Corp. (Nasdaq:DEVS), LanzaTech Global, Inc. (NASDAQ: LNZA), N2OFF, Inc. (NASDAQ: NITO), FireFly Metals Ltd. (TSX: FFM) Silver47 Exploration Corp. (TSXV:AGA), Groupe Dynamite Inc. (TSX:GRGD)

 

Read this in full at https://www.investorideas.com/news/2025/main/01311Stocks.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Cleantech Directories:

BluSky Carbon Inc. (CSE: BSKY) (OTCQB: BSKCF) is a renewable energy company that is in the business of putting Carbon back into the ground - where it belongs! The Company converts organic and industrial waste into biochar, renewable power and carbonate rocks, as well as the development and sale of carbon capture technology. BluSky's primary objectives are to (1) construct carbon removal equipment; (2) sell the biochar produced by the carbon removal equipment; and (3) sell carbon credits ‎generated from the production of biochar. The Company's business model is based on the growing need for carbon neutrality and demand to reduce CO2 emissions.

 

DevvStream Corp. (Nasdaq:DEVS) is a leading authority in the use of technology in carbon project development. The Company's mission is to create alignment between sustainability and profitability, helping organizations achieve their climate initiatives while directly improving their financial health. With a diverse approach to the carbon market, DevvStream operates across three strategic domains: (1) an offset portfolio consisting of nature-based, tech-based, and carbon sequestration credits for immediate sale to corporations and governments seeking to offset their most difficult-to-reduce emissions; (2) project investment, acquisitions, and industry consolidation to extend the company's reach, allowing it to become a full end-to-end solutions provider; and (3) project development, where the company serves as project manager for eligible activities such as EV charging in exchange for a percentage of generated credits.

 

LanzaTech Global, Inc. (NASDAQ: LNZA) is the carbon recycling company transforming waste carbon into sustainable fuels, chemicals, materials, and protein for everyday products. Using its bio-recycling technology, LanzaTech captures carbon generated by energy-intensive industries at the source, preventing it from being emitted into the air. LanzaTech then gives that captured carbon a new life as a clean replacement for virgin fossil carbon in everything from household cleaners and clothing fibers to packaging and fuels. By partnering with companies across the global supply chain like ArcelorMittal, Coty, Craghoppers, REI, and LanzaJet, LanzaTech is paving the way for a circular carbon economy.

 

N2OFF, Inc. (NASDAQ: NITO) is a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech. Through its operational activities it delivers integrated solutions for sustainable energy, greenhouse gas emissions reduction and safety, quality solutions for the agri- tech market. NTWO OFF Ltd., N2OFF's majority-owned Israeli subsidiary, aims to contribute in tackling greenhouse gas emissions, offering a pioneering solution to mitigate nitrous oxide (N2O) emissions, a potent greenhouse gas with 310 times the global warming impact of carbon dioxide. NTWO OFF Ltd., aims to promote agricultural practices that are both environmentally friendly and economically viable. N2OFF recently entered the solar PV market and will provide funding to Solterra Renewable Energy Ltd. for the current project in the total Capacity of 111 MWp, as well as potential future projects. Save Foods Ltd., N2OFF's majority-owned Israeli subsidiary, focuses on post-harvest treatments in fruit and vegetables to control and prevent pathogen contamination. N2OFF also has a minority ownership in Plantify Foods, Inc., a Canadian company listed on the TSXV that offers a wide range of clean-label healthy food options.

 

Brenmiller Energy, Ltd. (NASDAQ: BNRG) helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies.

 

New Stocks Added to the Mining Directories:

FireFly Metals Ltd. (TSX: FFM) is an emerging copper-gold company focused on advancing the high-grade Green Bay Copper-Gold project in Newfoundland, Canada. The Green Bay Copper-Gold Project currently hosts a mineral resource prepared in accordance with the JORC Code (2012 Edition) and NI 43-101 of 24.4Mt of measured and indicated resources at 1.9% for 460Kt CuEq and 34.5Mt of inferred resources at 2% for 690Kt CuEq. The Company has a clear strategy to rapidly grow the copper-gold resource to demonstrate a globally significant copper-gold asset.  FireFly has commenced a 130,000m diamond drilling program. FireFly holds a 70% interest in the high-grade Pickle Crow Gold Project in Ontario.  The current Inferred Resource stands at 11.9Mt at 7.2g/t for 2.8Moz gold, with exceptional discovery potential on the 500km2 tenement holding. The Company also holds a 90% interest in the Limestone Well Vanadium-Titanium Project in Western Australia.

 

Silver47 Exploration Corp. (TSXV:AGA) is focused on rapidly expanding its resource base of silver, gold, copper, zinc and lead, with the aim of reaching a milestone development decision in the next 3-5 years, while also driving new discoveries. Backed by industry leaders, the Company is advancing its flagship Red Mountain project in Alaska, which currently hosts 168.6 million ounces of silver at 336 g/t AgEq, equivalent to 1 million tonnes of zinc at 7% ZnEq or 2 million ounces of gold at 4 g/t AuEq. Silver47's initial focus is on increasing the silver-gold rich Dry Creek and West Tundra Flats resources at the eastern end of this district-scale land package, with an exploration target of 50Mt in the 300-400 g/t AgEq grade range for 480Moz Eq. The company's extensive land holdings of 942 state mining claims and one mining lease cover a 60km trend of polymetallic mineralization.

 

New Stocks Added to the Retail Directories:

Groupe Dynamite Inc. (TSX:GRGD) is a growth-oriented company striving for excellence in the fashion industry. Operating retail stores and digital experiences under two complementary and spirited banners—GARAGE and DYNAMITE—we offer a wide range of women's fashion apparel, catering to the needs of Generation Z and Millennials. With leading key operating metrics and a commitment to innovation and disciplined execution, we are proud to continue our ambitious growth plans. Guided by our mission, "Empowering YOU to be YOU, one outfit at a time," we are a values-led, inclusive organization committed to inspiring confidence and self-expression. Proudly rooted in the chic and vibrant city of Montréal, our culture, values and distinct brands position us to shape the future of fashion while attracting and inspiring the next generation of leaders and creators. Our ownership-mentality and entrepreneurial mindset is reflected in our Shared Success Program, through which all our 6,000 employees will have ownership exposure. This alignment of interests and values fosters collaboration, fuels innovation, and creates meaningful long-term value for our team and stakeholders alike.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

 

 

 

 

 

 

 

More Stocks Turning to Bitcoin for Long-Term Treasury Asset Strategy; Stocks Mentioned- (Nasdaq: $TZUP) @thumz_up , (NASDAQ: $MSTR), (Nasdaq: $HUT) (TSX: $HUT.TO), (NASDAQ: $MARA), (NASDAQ: $TSLA)

 

More Stocks Turning to Bitcoin for Long-Term Treasury Asset Strategy; Stocks Mentioned- (Nasdaq: $TZUP) @thumz_up , (NASDAQ: $MSTR), (Nasdaq: $HUT) (TSX: $HUT.TO), (NASDAQ: $MARA), (NASDAQ: $TSLA)

 

 

J

anuary 30, 2025 –Investorideas.com, a global news source and expert investing resource covering crypto and tech stocks issues a snapshot looking at stocks that are taking a long-term treasury asset strategy with cryptocurrency, featuring Thumzup Media Corporation (Nasdaq: TZUP), an emerging leader in social media branding and programmatic marketing solutions.

 

Stocks mentioned in this article include MicroStrategy Incorporated (NASDAQ: MSTR), Hut 8 Corp. (Nasdaq:HUT) (TSX: HUT), Maral Holdings Inc. (NASDAQ:MARA), Tesla (NASDAQ: TSLA).

 

A revolution in the financial markets is underway as more public companies and institutions look at Bitcoin (BTC), Ethereum (ETH) and Ripple (XRP) as part of their long-term treasury asset strategy. Although cryptocurrencies come with volatility, they offer global liquidity and accessibility 24/7 and the potential for long-term financial gain.

 

Always a leader in innovation, Tesla’s (NASDAQ: TSLA) Elon Musk led the charge for this new era, investing 1.5 billion in Bitcoin in 2021. Although Tesla sold most of its holdings, it established a precedent for bold thinking in digital assets.

 

Now under a Trump Presidency, cryptocurrency is gaining market acceptance and confidence and accelerating its role in corporate finance. The public companies on board with this new strategy are not just in the crypto space, they range from biotech to nanotech, to tech stocks.

 

Tech innovator Thumzup Media Corporation (NASDAQ: TZUP) is building on its current growth in social media branding and programmatic marketing solutions by making game changing moves in Bitcoin. According to a recent 8K Filing, On January 21, 2025, the Company purchased 9.323 Bitcoin (“BTC”) for $999,722, an average price of $107,231 per Bitcoin, inclusive of fees and expenses (“BTC Investment”).

 

Paid News Dissemination of behalf of TZUP

 

Read this news, featuring TZUP in full at https://www.investorideas.com/news/2025/cryptocurrency/01301Long-Term-Treasury-Asset-Strategy-with-Cryptocurrency.asp

 

As of January 21, 2025, Thumzup holds 19.106 Bitcoin at an average price of $104,650 per BTC.

 

On January 24^th Thumzup Media announced that its Board of Directors has authorized the allocation of up to 90% of the company's surplus cash to be held in Bitcoin. This decision supports the company's ongoing Bitcoin acquisition efforts as part of its Treasury Asset Strategy, announced on November 15, 2024.

 

This strategic move reflects Thumzup's confidence in Bitcoin as a long-term store of value and a groundbreaking asset class. By diversifying its treasury assets, the company aims to optimize its financial stability and create additional value for shareholders.

 

"I am excited about President Trump's announcement at Davos on Thursday, that he will make the United States the 'World Capital of Artificial Intelligence and Crypto.' Additionally, the President issued an Executive Order titled 'Strengthening American Leadership in Digital Financial Technology' on the same day. This order directs the Secretary of the Treasury, the Chairman of the Securities and Exchange Commission, and the Chairman of the Commodity Futures Trading Commission to establish the President's Working Group on Digital Asset Markets. The working group has been tasked with providing recommendations within 60 days on regulations concerning cryptocurrencies that should be rescinded or modified. I believe this initiative greatly strengthens the future of digital assets like Bitcoin and cryptocurrencies," said Robert Steele, Chief Executive Officer of Thumzup.

 

In addition to this initiative, Thumzup plans to begin paying gig-economy workers in BTC in the coming weeks, marking a significant step toward integrating Bitcoin into its operational framework. The company is working diligently to ensure compliance with all applicable laws and regulations while enabling a user-friendly payment experience for its workforce.

 

Looking at its core business, in late December Thumzup reported continued strong growth in its advertiser base, which now exceeds 600, just weeks after the Company announced it surpassed 500 advertisers. This momentum and robust growth trajectory should position Thumzup as an increasingly disruptive force in social media advertising.

 

"Our rapid expansion to over 600 advertisers highlights the strength of our disruptive advertising model," stated Robert Steele, CEO of Thumzup. "As a leader in authentic and creator driven social media advertising, our platform continues to empower brands with wider access to various audiences, while offering users real monetary incentives for our app users. This growth is a testament to the effectiveness of our innovative approach."

 

To further enhance its platform, Thumzup recently integrated with X (formerly Twitter), connecting advertisers with over 535 million monthly active users. Thumzup is also partnering with Tedras Global Solutions to leverage AI for improved ad targeting, campaign optimization and enhanced user experiences.

 

Thumzup is working to redefine the digital advertising landscape with its proprietary technology and scalable growth model. This unique approach combines a programmatic advertiser dashboard with a user-centric app that incentivizes engagement through direct cash payouts, disrupting traditional advertising norms and driving measurable results.

 

MicroStrategy Incorporated (NASDAQ: MSTR) is the world's first and largest Bitcoin Treasury Company. According to their website, “We are a publicly traded company that has adopted Bitcoin as our primary treasury reserve asset. By using proceeds from equity and debt financings, as well as cash flows from our operations, we strategically accumulate Bitcoin and advocate for its role as digital capital. Our treasury strategy is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. In addition, we provide industry-leading AI-powered enterprise analytics software, advancing our vision of Intelligence Everywhere. We leverage our development capabilities to explore innovation in Bitcoin applications, integrating analytics expertise with our commitment to digital asset growth. We believe our combination of operational excellence, strategic Bitcoin reserve, and focus on technological innovation positions us as a leader in both the digital asset and enterprise analytics sectors, offering a unique opportunity for long-term value creation.”

 

On January 27^th MicroStrategy announced that, subject to market and other conditions, it intends to offer, in a public offering registered under the Securities Act of 1933, as amended (the “Securities Act”), 2,500,000 shares of MicroStrategy’s Series A Perpetual Strike Preferred Stock.

 

From the news: MicroStrategy intends to use the net proceeds from the offering for general corporate purposes, including the acquisition of Bitcoin and for working capital.

 

Continued: The perpetual strike preferred stock will have a liquidation preference of $100 per share and will accumulate cumulative dividends at a fixed rate that will be determined at the pricing of the offering. Regular dividends on the perpetual strike preferred stock will be payable when, as and if declared by MicroStrategy’s board of directors, out of funds legally available for their payment to the extent paid in cash, quarterly in arrears on March 31, June 30, September 30 and December 31 of each year, beginning on March 31, 2025. Declared regular dividends on the perpetual strike preferred stock will be payable, at MicroStrategy's election, in cash, shares of class A common stock or a combination of cash and shares of class A common stock, in the manner, and subject to the provisions, described in the prospectus supplement for the offering.

 

Bitcoin Magazine recently reported, “MicroStrategy has once again solidified its position as the largest corporate holder of Bitcoin, announcing the acquisition of an additional 10,100 BTC for $1.1 billion. The latest purchase, made at an average price of $105,596 per Bitcoin, occurred just before a market correction saw Bitcoin's price dip 6% below $100,000.”

 

Also betting on the long-term potential of Bitcoin, Hut 8 Corp. (Nasdaq:HUT) (TSX: HUT), a leading, vertically-integrated operator of large-scale energy infrastructure and one of North America’s largest Bitcoin miners, in mid-December announced the purchase of approximately 990 Bitcoin. The aggregate purchase price of the acquired Bitcoin was approximately $100 million, or an average of approximately $101,710 per Bitcoin.

 

Combined with the Bitcoin held prior to this purchase, Hut 8’s strategic Bitcoin reserve now totals 10,096 Bitcoin with a market value of more than $1 billion as of December 18, 2024. Based on publicly available information, the Company believes this positions it as one of the ten largest corporate owners of Bitcoin in the world. The 10,096 Bitcoin held in reserve were acquired through low-cost production and the strategic at-market purchase announced today for a realized average cost of $24,484 per Bitcoin. The purchased Bitcoin will play a central role in an innovative financing model for the Company’s previously announced fleet upgrade.

 

The trend for public companies investing in Bitcoin is so dominant in the crypto space that Coingecko.com now reports on 32 public company holdings.

 

Following just behind Microstrategy on their list is Mara Holdings Inc. (NASDAQ:MARA) with a total of 26,842 Bitcoin and according to their report, Hut 8 Corp. (Nasdaq:HUT) has now moved to 6^th position. And even though Tesla (NASDAQ: TSLA) sold off most of its holdings, it is still ranked in the top 10 at 4^th.

 

With President Trump’s bullish sentiment towards crypto, this trend is expected to increase.   

 

Research more tech stocks with Investorideas.com free stock directory

https://www.investorideas.com/TSS/Stock_List.asp

 

Research more crypto stocks at Investorideas.com

https://www.investorideas.com/Bitcoin-Cryptocurrency/Stocks_List.asp#

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

Disclaimer/Disclosure: This article featuring TZUP is paid for content and news dissemination. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

More disclaime: https://www.investorideas.com/About/Disclaimer.asp

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.

800 665 0411

 

 

Get more Bitcoin, Blockchain, Digital Currency stock investor ideas - news, articles, podcasts and stock directories

 

Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Cancer Clinical Trial update

 

 

Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Cancer Clinical Trial update

 

 

Investorideas.com (www.investorideas.com) a go-to platform for big investing ideas for stock traders, including  biotech  and medical tech stocks reports on trading and news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

Aethlon is trading up today, currently at $0.6930, up 0.0700, gaining 11.1643% on over 2.1 Million shares. The stock has a day’s high of $0.75 as of this report.

 

Aethlon Medical, Inc. (Nasdaq: AEMD) today announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia, and treated with the Hemopurifer on January 29, 2025, by Prof. Toby Coates and the dialysis staff.

 

Paid News Dissemination of behalf of AEMD.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2025/biotech/01291Medical-Therapeutic-Stock-AEMD.asp

 

The patient treated was determined to have progressive disease following a two-month "run -in" period of the anti-PD-1 drug Nivolumab. During this period, serial measurements of extracellular vesicles (EVs) and anti-tumor T cell activity were obtained. The patient was then treated with the Aethlon Hemopurifier for 4 hours on a single day and tolerated the procedure without complications. The patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.

 

"Treatment of the first patient represents the achievement of a critical milestone for Aethlon Medical in the clinical development of the Hemopurifier in Oncology," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. "We are excited to receive the data from this first treatment cohort, anticipating insights into how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors".

 

Currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

 

The primary endpoint of the approximately 18-patient, safety, feasibility, and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run-in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

 

Recent news release

https://www.investorideas.com/news/2025/01291AEMD-Treats-First-Patient-in-Australian-Hemopurifier-Cancer-Trial.asp

 

Biotech stocks to watch:

Research more Biotech and medical technology stocks with Investorideas.com free stock directory

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Disclaimer/Disclosure: This news alert for AEMD is part of Investorideas.com paid content on behalf of Aethlon Medical. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more.. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy poilicy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, IR, PR and social media, podcast sponsorship and ticker tag content creation services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about digital advertising and guest posts/sponsored posts

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

 

Contact Investorideas.com

800 665 0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Treats First Patient in Australian Hemopurifier® Cancer Trial

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Treats First Patient in Australian Hemopurifier® Cancer Trial

 

First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital

 

Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies

 

SAN DIEGO, CA- January 29, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia, and treated with the Hemopurifer on January 29, 2025, by Prof. Toby Coates and the dialysis staff.

 

The patient treated was determined to have progressive disease following a two-month "run -in" period of the anti-PD-1 drug Nivolumab. During this period, serial measurements of extracellular vesicles (EVs) and anti-tumor T cell activity were obtained. The patient was then treated with the Aethlon Hemopurifier for 4 hours on a single day and tolerated the procedure without complications. The patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.

 

Paid News Dissemination of behalf of AEMD.

 

Read this news featuring AEMD in full at https://www.investorideas.com/news/2025/01291AEMD-Treats-First-Patient-in-Australian-Hemopurifier-Cancer-Trial.asp

 

"Treatment of the first patient represents the achievement of a critical milestone for Aethlon Medical in the clinical development of the Hemopurifier in Oncology," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. "We are excited to receive the data from this first treatment cohort, anticipating insights into how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors".

 

Currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

 

The primary endpoint of the approximately 18-patient, safety, feasibility, and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run-in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

 

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation. The Hemopurifier is an extracorporeal device that is used in concert with a blood pump. The device incorporates plasma separation, size exclusion, and affinity binding to an affinity resin containing a plant lectin. Mannose on the surface of enveloped viruses and extracellular vesicles binds to the plant lectin within the device. Extracellular vesicles released from solid tumors have been implicated in the spread of cancers known as metastasis as well as in the resistance to immunotherapy and chemotherapeutic agents. Removal of enveloped viruses and extracellular vesicles has been observed in in vitro studies and in human subjects. The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard-of-care therapy. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. is a publicly traded medical device company based in San Diego, California. The company aims to leverage its therapeutic device, The Hemopurifier, to remove enveloped viruses and extracellular vesicles from biologic fluids. Aethlon Medical's innovative platform is enabling the development of new options for cancer and life-threatening infectious diseases. For more information on Aethlon Medical, Inc. and its clinical development program, visit www.AethlonMedical.com and follow the company on LinkedIn.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such include, without limitation, the number of patients who receive pembrolizumab or nivolumab that will have lasting clinical responses to these agents; the possibility of novel treatment strategies; how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors; the efficacy of continued clinical trials. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

 

SOURCE Aethlon Medical, Inc.

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: 

https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories